Quanterix rises on 'breakthrough device' tag for its blood test for Alzheimer’s Disease

Quanterix

04/03/2024 16:19

** Shares of diagnostic company Quanterix  QTRX.O  rise 1.2%
to $27.31 
    ** Co announces that the U.S. FDA has granted its blood test
'breakthrough device' designation
    ** 'Breakthrough device' designation helps patients gain
access to medical devices in treatments for which no approved or
cleared alternatives exist
     ** The blood test called Simoa helps in detecting a
protein, p-Tau 217, to help diagnose Alzheimer’s Disease
    ** The test is not intended as a stand-alone test and its
results will be interpreted along with other diagnostic tools -
QTRX
    ** Including session moves, stock has doubled in the last 12
months  

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))